Targeting Oncogenic Mutant p53 for Cancer Therapy

Lane, 2010, p53 Research: the past thirty years and the next thirty years, Cold Spring Harb Perspect Biol, 2, a000893, 10.1101/­cshperspect.a000893

Levav-Cohen, 2014, The p53-Mdm2 loop: a critical juncture of stress response, Subcell Biochem, 85, 161, 10.1007/978-94-017-9211-0_9

Vaseva, 2009, The mitochondrial p53 pathway, Biochim Biophys Acta, 1787, 414, 10.1016/j.bbabio.2008.10.005

Pant, 2014, Limiting the power of p53 through the ubiquitin proteasome pathway, Genes Dev, 28, 1739, 10.1101/gad.247452.114

Muller, 2013, p53 mutations in cancer, Nat Cell Biol, 15, 2, 10.1038/ncb2641

Rivlin, 2011, Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis, Genes Cancer, 2, 466, 10.1177/1947601911408889

Rivlin, 2015, p53 orchestrates between normal differentiation and cancer, Semin Cancer Biol, 32, 10, 10.1016/j.semcancer.2013.12.006

Joerger, 2008, Structural biology of the tumor suppressor p53, Annu Rev Biochem, 77, 557, 10.1146/annurev.biochem.77.060806.091238

Goldstein, 2011, Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies, Cancer Gene Ther, 18, 2, 10.1038/cgt.2010.63

Terzian, 2008, The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss, Genes Dev, 22, 1337, 10.1101/gad.1662908

Cavenee, 1991, Molecular genetics of human cancer predisposition and progression, Mutat Res, 247, 199, 10.1016/0027-5107(91)90015-G

Gonzalez, 1995, Loss of heterozygosity and mutation analysis of the p16 (9p21) and p53 (17p13) genes in squamous cell carcinoma of the head and neck, Clin Cancer Res, 1, 1043

Alexandrova, 2015, Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment, Nature, 523, 352, 10.1038/nature14430

Masciarelli, 2014, Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells, Oncogene, 33, 1601, 10.1038/onc.2013.106

Weisz, 2007, Transcription regulation by mutant p53, Oncogene, 26, 2202, 10.1038/sj.onc.1210294

Freed-Pastor, 2012, Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway, Cell, 148, 244, 10.1016/j.cell.2011.12.017

Foster, 1999, Pharmacological rescue of mutant p53 conformation and function, Science, 286, 2507, 10.1126/science.286.5449.2507

Zhang, 1994, A temperature-sensitive mutant of human p53, EMBO J, 13, 2535, 10.1002/j.1460-2075.1994.tb06543.x

Selivanova, 1998, Reactivation of mutant p53: a new strategy for cancer therapy, Semin Cancer Biol, 8, 369, 10.1006/scbi.1998.0099

Friedler, 2002, A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants, Proc Natl Acad Sci U S A, 99, 937, 10.1073/pnas.241629998

Selivanova, 1997, Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain, Nat Med, 3, 632, 10.1038/nm0697-632

Nikolova, 2000, Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations, EMBO J, 19, 370, 10.1093/emboj/19.3.370

Bykov, 2002, Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound, Nat Med, 8, 282, 10.1038/nm0302-282

Liu, 2001, Biological significance of a small highly conserved region in the N terminus of the p53 tumour suppressor protein, J Mol Biol, 313, 711, 10.1006/jmbi.2001.5082

Tang, 2007, CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice, J Clin Invest, 117, 3753, 10.1172/JCI32481

Tanner, 2004, CP-31398, a putative p53-stabilizing molecule tested in mammalian cells and in yeast for its effects on p53 transcriptional activity, J Negat Results Biomed, 3, 5, 10.1186/1477-5751-3-5

Rippin, 2002, Characterization of the p53-rescue drug CP-31398 in vitro and in living cells, Oncogene, 21, 2119, 10.1038/sj.onc.1205362

Zache, 2008, Mutant p53 targeting by the low molecular weight compound STIMA-1, Mol Oncol, 2, 70, 10.1016/j.molonc.2008.02.004

Lambert, 2009, PRIMA-1 reactivates mutant p53 by covalent binding to the core domain, Cancer Cell, 15, 376, 10.1016/j.ccr.2009.03.003

Lambert, 2010, Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis, Oncogene, 29, 1329, 10.1038/onc.2009.425

Bykov, 2005, Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs, J Biol Chem, 280, 30384, 10.1074/jbc.M501664200

Zhao, 2010, Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA, Cell Cycle, 9, 1847, 10.4161/cc.9.9.11545

Burmakin, 2013, Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro, Clin Cancer Res, 19, 5092, 10.1158/1078-0432.CCR-12-2211

Blanden, 2015, Synthetic metallochaperone ZMC1 rescues mutant p53 conformation by transporting zinc into cells as an ionophore, Mol Pharmacol, 87, 825, 10.1124/mol.114.097550

Yu, 2012, Allele-specific p53 mutant reactivation, Cancer Cell, 21, 614, 10.1016/j.ccr.2012.03.042

Yu, 2014, Small molecule restoration of wildtype structure and function of mutant p53 using a novel zinc-metallochaperone based mechanism, Oncotarget, 5, 8879, 10.18632/oncotarget.2432

Hiraki, 2015, Small-molecule reactivation of mutant p53 to wild-type-like p53 through the p53-Hsp40 regulatory axis, Chem Biol, 22, 1206, 10.1016/j.chembiol.2015.07.016

Liu, 2013, Small molecule induced reactivation of mutant p53 in cancer cells, Nucleic Acids Res, 41, 6034, 10.1093/nar/gkt305

Wassman, 2013, Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53, Nat Commun, 4, 1407, 10.1038/ncomms2361

Weinmann, 2008, A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis, Cell Death Differ, 15, 718, 10.1038/sj.cdd.4402301

Demma, 2010, SCH529074, a small molecule activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53, J Biol Chem, 285, 10198, 10.1074/jbc.M109.083469

Pluquet, 2003, Activation of p53 by the cytoprotective aminothiol WR1065: DNA-damage-independent pathway and redox-dependent modulation of p53 DNA-binding activity, Biochem Pharmacol, 65, 1129, 10.1016/S0006-2952(02)01655-6

Pluquet, 2003, The cytoprotective aminothiol WR1065 activates p53 through a non-genotoxic signaling pathway involving c-Jun N-terminal kinase, J Biol Chem, 278, 11879, 10.1074/jbc.M207396200

Shen, 2001, Binding of the aminothiol WR-1065 to transcription factors influences cellular response to anticancer drugs, J Pharmacol Exp Ther, 297, 1067

North, 2002, Restoration of wild-type conformation and activity of a temperature-sensitive mutant of p53 (p53(V272M)) by the cytoprotective aminothiol WR1065 in the esophageal cancer cell line TE-1, Mol Carcinog, 33, 181, 10.1002/mc.10038

Wischhusen, 2003, CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death, Oncogene, 22, 8233, 10.1038/sj.onc.1207198

Rao, 2013, Chemopreventive effects of the p53-modulating agents CP-31398 and Prima-1 in tobacco carcinogen-induced lung tumorigenesis in A/J mice, Neoplasia, 15, 1018, 10.1593/neo.131256

Zandi, 2011, PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53, Clin Cancer Res, 17, 2830, 10.1158/1078-0432.CCR-10-3168

Liang, 2009, PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein, Int J Oncol, 35, 1015, 10.3892/ijo_00000416

Zache, 2008, PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53, Cell Oncol, 30, 411, 10.3233/CLO-2008-0440

Bykov, 2014, Mutant p53 reactivation by small molecules makes its way to the clinic, FEBS Lett, 588, 2622, 10.1016/j.febslet.2014.04.017

Duffy, 2014, p53 as a target for the treatment of cancer, Cancer Treat Rev, 40, 1153, 10.1016/j.ctrv.2014.10.004

Saha, 2014, Small molecule MIRA-1 induces in vitro and in vivo anti-myeloma activity and synergizes with current anti-myeloma agents, Br J Cancer, 110, 2224, 10.1038/bjc.2014.164

Rivera, 1999, Selective toxicity of the tricyclic thiophene NSC 652287 in renal carcinoma cell lines: differential accumulation and metabolism, Biochem Pharmacol, 57, 1283, 10.1016/S0006-2952(99)00046-5

Nieves-Neira, 1999, DNA protein cross-links produced by NSC 652287, a novel thiophene derivative active against human renal cancer cells, Mol Pharmacol, 56, 478, 10.1124/mol.56.3.478

Issaeva, 2004, Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors, Nat Med, 10, 1321, 10.1038/nm1146

Grinkevich, 2009, Ablation of key oncogenic pathways by RITA-reactivated p53 is required for efficient apoptosis, Cancer Cell, 15, 441, 10.1016/j.ccr.2009.03.021

Margalit, 2012, Zinc supplementation augments in vivo antitumor effect of chemotherapy by restoring p53 function, Int J cancer, 131, E562, 10.1002/ijc.26441

Pintus, 2013, The substitutions G245C and G245D in the Zn(2+)-binding pocket of the p53 protein result in differences of conformational flexibility of the DNA-binding domain, J Biomol Struct Dyn, 31, 78, 10.1080/07391102.2012.691364

Puca, 2011, Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs, Cell Cycle, 10, 1679, 10.4161/cc.10.10.15642

Kung, 2004, Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway, Cancer Cell, 6, 33, 10.1016/j.ccr.2004.06.009

Staab, 2007, Effects of HIF-1 inhibition by chetomin on hypoxia-related transcription and radiosensitivity in HT 1080 human fibrosarcoma cells, BMC Cancer, 7, 213, 10.1186/1471-2407-7-213

Kessler, 2010, HIF-1alpha inhibition by siRNA or chetomin in human malignant glioma cells: effects on hypoxic radioresistance and monitoring via CA9 expression, BMC Cancer, 10, 605, 10.1186/1471-2407-10-605

Boeckler, 2008, Targeted rescue of a destabilized mutant of p53 by an in silico screened drug, Proc Natl Acad Sci U S A, 105, 10360, 10.1073/pnas.0805326105

Lukashchuk, 2007, Ubiquitination and degradation of mutant p53, Mol Cell Biol, 27, 8284, 10.1128/MCB.00050-07

Blagosklonny, 1995, Geldanamycin selectively destabilizes and conformationally alters mutated p53, Oncogene, 11, 933

Egorin, 1998, Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations, Cancer Res, 58, 2385

Wang, 2003, Phosphorylation and hsp90 binding mediate heat shock stabilization of p53, J Biol Chem, 278, 2066, 10.1074/jbc.M206697200

Li, 2011, Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells, Mol Cancer Res, 9, 577, 10.1158/1541-7786.MCR-10-0534

Blagosklonny, 2005, Why therapeutic response may not prolong the life of a cancer patient: selection for oncogenic resistance, Cell Cycle, 4, 1693, 10.4161/cc.4.12.2259

Li, 2011, SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis, Cell Death Differ, 18, 1904, 10.1038/cdd.2011.71

Marks, 2007, Discovery and development of SAHA as an anticancer agent, Oncogene, 26, 1351, 10.1038/sj.onc.1210204

Yan, 2011, Mutant p53 protein is targeted by arsenic for degradation and plays a role in arsenic-mediated growth suppression, J Biol Chem, 286, 17478, 10.1074/jbc.M111.231639

Yan, 2014, Arsenic trioxide reactivates proteasome-dependent degradation of mutant p53 protein in cancer cells in part via enhanced expression of Pirh2 E3 ligase, PLoS One, 9, e103497, 10.1371/journal.pone.0103497

Wang, 2011, Gambogic acid-induced degradation of mutant p53 is mediated by proteasome and related to CHIP, J Cell Biochem, 112, 509, 10.1002/jcb.22941

Vakifahmetoglu-Norberg, 2013, Chaperone-mediated autophagy degrades mutant p53, Genes Dev, 27, 1718, 10.1101/gad.220897.113

Vakifahmetoglu-Norberg, 2013, A degradative detour for mutant TP53, Autophagy, 9, 2158, 10.4161/auto.26338

Yi, 2013, Targeting mutant p53 by a SIRT1 activator YK-3-237 inhibits the proliferation of triple-negative breast cancer cells, Oncotarget, 4, 984, 10.18632/oncotarget.1070

Zhang, 2015, Small-molecule NSC59984 restores p53 pathway signaling and antitumor effects against colorectal cancer via p73 activation and degradation of mutant p53, Cancer Res, 75, 3842, 10.1158/0008-5472.CAN-13-1079

Paranjpe, 2013, Degradation of NF-kappaB, p53 and other regulatory redox-sensitive proteins by thiol-conjugating and -nitrosylating drugs in human tumor cells, Carcinogenesis, 34, 990, 10.1093/carcin/bgt032

Ramalingam, 2015, A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1), Ann Oncol, 26, 1741, 10.1093/annonc/mdv220

Goyal, 2015, A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma, Invest New Drugs, 33, 128, 10.1007/s10637-014-0164-8

Jhaveri, 2014, A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer, Clin Breast Cancer, 14, 154, 10.1016/j.clbc.2013.12.012

Yan, 2013, Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8, Oncogene, 32, 599, 10.1038/onc.2012.81

Beauchamp, 2012, A new era for an ancient drug: arsenic trioxide and Hedgehog signaling, Vitam Horm, 88, 333, 10.1016/B978-0-12-394622-5.00015-8

Jiang, 2010, Cooperation of tumor-derived HBx mutants and p53-249(ser) mutant in regulating cell proliferation, anchorage-independent growth and aneuploidy in a telomerase-immortalized normal human hepatocyte-derived cell line, Int J Cancer, 127, 1011, 10.1002/ijc.25118

Hughes, 2011, Arsenic exposure and toxicology: a historical perspective, Toxicol Sci, 123, 305, 10.1093/toxsci/kfr184

Gu, 2008, Gambogic acid mediates apoptosis as a p53 inducer through down-regulation of mdm2 in wild-type p53-expressing cancer cells, Mol Cancer Ther, 7, 3298, 10.1158/1535-7163.MCT-08-0212

Liu, 2011, Beclin1 controls the levels of p53 by regulating the deubiquitination activity of USP10 and USP13, Cell, 147, 223, 10.1016/j.cell.2011.08.037

Yuan, 2010, USP10 regulates p53 localization and stability by deubiquitinating p53, Cell, 140, 384, 10.1016/j.cell.2009.12.032

Kong, 2010, A boronic acid chalcone analog of combretastatin A-4 as a potent anti-proliferation agent, Bioorg Med Chem, 18, 971, 10.1016/j.bmc.2009.11.003

Kona, 2011, Disulfiram, and disulfiram derivatives as novel potential anticancer drugs targeting the ubiquitin-proteasome system in both preclinical and clinical studies, Curr Cancer Drug Targets, 11, 338, 10.2174/156800911794519798

Nechushtan, 2015, A phase IIb trial assessing the addition of disulfiram to chemotherapy for the treatment of metastatic non-small cell lung cancer, Oncologist, 20, 366, 10.1634/theoncologist.2014-0424

Petersen, 1992, The pharmacology and toxicology of disulfiram and its metabolites, Acta Psychiatr Scand Suppl, 369, 7, 10.1111/j.1600-0447.1992.tb03309.x

Mathieu, 2015, Effects of pesticide chemicals on the activity of metabolic enzymes: focus on thiocarbamates, Expert Opin Drug Metab Toxicol, 11, 81, 10.1517/17425255.2015.975691

Davies, 2001, Degradation of oxidized proteins by the 20S proteasome, Biochimie, 83, 301, 10.1016/S0300-9084(01)01250-0

Velu, 2007, Human p53 is inhibited by glutathionylation of cysteines present in the proximal DNA-binding domain during oxidative stress, Biochemistry, 46, 7765, 10.1021/bi700425y

Yusuf, 2010, Cys-141 glutathionylation of human p53: studies using specific polyclonal antibodies in cancer samples and cell lines, Free Radic Biol Med, 49, 908, 10.1016/j.freeradbiomed.2010.06.020

Olivier, 2010, TP53 mutations in human cancers: ­origins, consequences, and clinical use, Cold Spring Harb Perspect Biol, 2, a001008, 10.1101/cshperspect.a001008

Micale, 2014, Molecular analysis, pathogenic mechanisms, and readthrough therapy on a large cohort of Kabuki syndrome patients, Hum Mutat, 35, 841, 10.1002/humu.22547

Floquet, 2011, Rescue of non-sense mutated p53 tumor suppressor gene by aminoglycosides, Nucleic Acids Res, 39, 3350, 10.1093/nar/gkq1277

Martin, 2014, Identification and characterization of small molecules that inhibit nonsense-mediated RNA decay and suppress nonsense p53 mutations, Cancer Res, 74, 3104, 10.1158/0008-5472.CAN-13-2235

Kanasty, 2013, Delivery materials for siRNA therapeutics, Nat Mater, 12, 967, 10.1038/nmat3765

Lim, 2009, Mutant p53 mediates survival of breast cancer cells, Br J Cancer, 101, 1606, 10.1038/sj.bjc.6605335

Hui, 2006, Mutant p53 in MDA-MB-231 breast cancer cells is stabilized by elevated phospholipase D activity and contributes to survival signals generated by phospholipase D, Oncogene, 25, 7305, 10.1038/sj.onc.1209735

Zhu, 2011, RNA interference targeting mutant p53 inhibits growth and induces apoptosis in DU145 human prostate cancer cells, Med Oncol, 28, S381, 10.1007/s12032-010-9679-9

Zhu, 2013, Silencing of mutant p53 by siRNA induces cell cycle arrest and apoptosis in human bladder cancer cells, World J Surg Oncol, 11, 22, 10.1186/1477-7819-11-22

Martinez, 2002, Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways, Proc Natl Acad Sci U S A, 99, 14849, 10.1073/pnas.222406899

Kravchenko, 2008, Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway, Proc Natl Acad Sci U S A, 105, 6302, 10.1073/pnas.0802091105

Shimoyama, 2011, Statins are logical candidates for overcoming limitations of targeting therapies on malignancy: their potential application to gastrointestinal cancers, Cancer Chemother Pharmacol, 67, 729, 10.1007/s00280-011-1583-2

Sorrentino, 2014, Metabolic control of YAP and TAZ by the mevalonate pathway, Nat Cell Biol, 16, 357, 10.1038/ncb2936

Kaelin, 2005, The concept of synthetic lethality in the context of anticancer therapy, Nat Rev Cancer, 5, 689, 10.1038/nrc1691

Wang, 1996, UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53, J Natl Cancer Inst, 88, 956, 10.1093/jnci/88.14.956

Sur, 2009, A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53, Proc Natl Acad Sci U S A, 106, 3964, 10.1073/pnas.0813333106

Wang, 2001, Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator, Cancer Res, 61, 8211

Reguart, 2014, Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression, Lung Cancer, 84, 161, 10.1016/j.lungcan.2014.02.011

Krug, 2015, Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial, Lancet Oncol, 16, 447, 10.1016/S1470-2045(15)70056-2

Yoo, 2014, Phase I and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancer, Invest New Drugs, 32, 271, 10.1007/s10637-013-9983-2

Yanada, 2013, Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia, Blood, 121, 3095, 10.1182/blood-2012-11-466862

Efficace, 2014, Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: health-related quality-of-life outcomes, J Clin Oncol, 32, 3406, 10.1200/JCO.2014.55.3453

Qu, 2011, [Multicenter phase II clinical trial of arsenic trioxide injection in the treatment of primary hepatocarcinoma], Zhonghua Zhong Liu Za Zhi, 33, 697

Verma, 1990, A randomized phase II study of cisplatin alone versus cisplatin plus disulfiram, Am J Clin Oncol, 13, 119, 10.1097/00000421-199004000-00007

Karlsson, 2000, Biosensor analysis of drug-target interactions: direct and competitive binding assays for investigation of interactions between thrombin and thrombin inhibitors, Anal Biochem, 278, 1, 10.1006/abio.1999.4406

Lamos, 2006, Mixed isotope photoaffinity reagents for identification of small-molecule targets by mass spectrometry, Angew Chem Int Ed Engl, 45, 4329, 10.1002/anie.200600743

Lomenick, 2009, Target identification using drug affinity responsive target stability (DARTS), Proc Natl Acad Sci U S A, 106, 21984, 10.1073/pnas.0910040106

Jafari, 2014, The cellular thermal shift assay for evaluating drug target interactions in cells, Nat Protoc, 9, 2100, 10.1038/nprot.2014.138

Lammens, 2010, Regular surveillance for Li-Fraumeni syndrome: advice, adherence and perceived benefits, Fam Cancer, 9, 647, 10.1007/s10689-010-9368-z

Wang, 2010, Targeting p53 for novel anticancer therapy, Transl Oncol, 3, 1, 10.1593/tlo.09250

Khoo, 2014, Drugging the p53 pathway: understanding the route to clinical efficacy, Nat Rev Drug Discov, 13, 217, 10.1038/nrd4236

Tongyang, 2015, [Synthetic lethal genes to mutant p53], Yi Chuan, 37, 321, 10.16288/j.yczz.14-277

Shaheen, 2011, Synthetic lethality: exploiting the addiction of cancer to DNA repair, Blood, 117, 6074, 10.1182/blood-2011-01-313734

Wang, 2013, Identification of potential synthetic lethal genes to p53 using a computational biology approach, BMC Med Genomics, 6, 30, 10.1186/1755-8794-6-30